Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Yubo International Biotech Limited (YBGJ : OTC)

• Company Description    MAGNA-LAB INC. is a development stage company. Co. has developed and now markets and intends to produce the MAGNA-SLn, the first of Co.'s proposed series of anatomy specific MRI (Magnetic Resonance Imaging) products which are smaller and cost less to own, install and operate than present ``whole body`` MRI systems. Number of Employees: 20

• Price / Volume Information    Yesterday's Closing Price: $0.09 Daily Weekly Monthly 20 Day Moving Average: 4 shares Shares Outstanding: 118.18 (millions) Market Capitalization: $10.27 (millions) Beta: 4.40 52 Week High: $0.20 52 Week Low: $0.03 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.00% -3.79% 12 Week -2.25% -9.26% Year To Date -8.53% -16.79%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Room 105 Building 5 31 Xishiku Avenue - Beijing,F4 100034 CHN ph: 86-010-6615-5141 fax: 516-595-1159 None http://www.yubogroup.com

• General Corporate Information    Officers Jun Wang - Chief Executive Officer; President and Director Lina Liu - Chief Financial Officer; Treasurer and Director Yang Wang - Director Zhihui Bai - Director Seymour Kessler - Director Peer Information Yubo International Biotech Limited (ABMD) Yubo International Biotech Limited (DMDS) Yubo International Biotech Limited (CPWY.) Yubo International Biotech Limited (EQUR) Yubo International Biotech Limited (ECIA) Yubo International Biotech Limited (FMS) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED INSTRUMENTS Sector: Medical CUSIP: 988366100 SIC: 3845 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/22 Next Expected EPS Date: 07/14/23 Share - Related Items Shares Outstanding: 118.18 Most Recent Split Date: 3.00 (0.01:1) Beta: 4.40 Market Capitalization: $10.27 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/14/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 41.72 EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: 929.51% vs. Previous Quarter: 135.45% ROE 03/31/23 - - 12/31/22 - - 09/30/22 - - ROA 03/31/23 - -30.83 12/31/22 - -33.04 09/30/22 - -40.54 Current Ratio 03/31/23 - 0.24 12/31/22 - 0.30 09/30/22 - 0.26 Quick Ratio 03/31/23 - 0.16 12/31/22 - 0.17 09/30/22 - 0.22 Operating Margin 03/31/23 - -383.08 12/31/22 - -1,155.51 09/30/22 - -460.24 Net Margin 03/31/23 - -383.08 12/31/22 - -1,155.51 09/30/22 - -460.24 Pre-Tax Margin 03/31/23 - -383.08 12/31/22 - -1,155.51 09/30/22 - -460.24 Book Value 03/31/23 - -0.01 12/31/22 - 0.00 09/30/22 - -0.01 Inventory Turnover 03/31/23 - 0.70 12/31/22 - 0.28 09/30/22 - 0.87 Debt-to-Equity 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Capital 03/31/23 - - 12/31/22 - - 09/30/22 - -

Powered by Zacks Investment Research ©